Compare Kinder Morgan Inc (KMI) vs Recursion Pharmaceuticals Inc (RXRX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Kinder Morgan Inc vs Recursion Pharmaceuticals Inc — how do they compare? Kinder Morgan Inc trades at $32.49 (market cap $71.81B), while Recursion Pharmaceuticals Inc trades at $4.36 (market cap $2.14B). The key difference: Kinder Morgan Inc is far larger — about 33.6× Recursion Pharmaceuticals Inc's market cap, and Kinder Morgan Inc pays a 3.66% dividend while Recursion Pharmaceuticals Inc pays none. Which is the better fit depends on your goals — on Pluang, investors hold Kinder Morgan Inc for 150 Days and Recursion Pharmaceuticals Inc for 23 Days on average.
| KMI | RXRX | |
|---|---|---|
Market Cap | $71.81B | $2.14B |
Volume | 16,921,908 | 30,789,535 |
Sector | Energy | Health |
52-Week High | $34.31 | $6.79 |
52-Week Low | $25.84 | $2.84 |
Typical Hold Time | 150 Days | 23 Days |
Enterprise Value | $103.86B | $1.66B |
Dividend Yield | 3.66% | — |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Kinder Morgan (KMI) trades at $32.25, up 1.35% with a bullish technical signal and strong fundamental performance. The company has beaten earnings estimates for three consecutive quarters, posting 18% net income margin growth in 2025. Analyst consensus shows mixed sentiment with 47% buy ratings and a $37.20 price target, representing 15% upside potential. Recent news highlights the company's $6-7B growth runway from Southeast gas demand and data center expansion.
KMI offers investors stable fee-based revenue from energy infrastructure with a compelling dividend yield. The stock presents growth potential from natural gas demand trends but faces risks from energy market volatility and high debt levels. Current valuation metrics appear reasonable given the company's profitability and growth backlog, though technical indicators show some overbought conditions near-term.
Recursion Pharmaceuticals (RXRX) trades at $3.95, down 7.49% today, with a mixed technical picture showing bullish moving averages but neutral oscillators. The company reported Q2 2026 earnings miss after two consecutive beats, while maintaining negative profitability metrics with a -961.97% net income margin. Recent strategic partnerships with Tempus and Roche aim to expand the AI-driven drug discovery pipeline through 2028.
RXRX presents high-risk growth potential with strong analyst support (40% buy rating) but faces substantial financial challenges including persistent losses and negative cash flow from operations. The stock's investment case hinges on successful pipeline development and partnership monetization, though current valuation appears stretched at 37.14x sales given the lack of profitability.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Top news
Latest headlines on both assets
Top news
Latest headlines on both assets
About Kinder Morgan Inc
Kinder Morgan is one of the largest midstream energy firms in North America, with an interest in or an operator on about 83,000 miles in pipelines and over 140 storage terminals. The company is active in the transportation, storage, and processing of natural gas, crude oil, refined products, natural gas liquids, and carbon dioxide. The majority of Kinder Morgan's cash flows stem from fee-based contracts for handling, moving, and storing fossil fuel products.
Read more on KMI →About Recursion Pharmaceuticals Inc
Recursion Pharmaceuticals, Inc. is a clinical-stage biotechnology company leveraging artificial intelligence (AI) and machine learning to industrialize drug discovery. The company's unique approach combines one of the world's largest biological and chemical datasets with automated wet-lab and computational systems to map human biology and identify potential therapeutic candidates across a range of diseases, including oncology and rare diseases. Recursion aims to accelerate the traditionally slow and expensive process of drug development.
Read more on RXRX →
